Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel

eJHaem

article

Xavier Leleu¹  Eirini Katodritou²  Thomas Kuehr³  Evangelos Terpos⁴  Jo Caers⁵  Renato Zambello⁶  Alessandra Brescianini⁷  Tony Liang⁸  Sally Wetten⁹  Sorina N. Badelita^1,10 

[1] Department of Haematology, University Hospital Centre La Miletrie and Inserm;Department of Haematology, Theagenio Cancer Hospital;Department of Internal Medicine IV, Academic Teaching Hospital Wels-Grieskirchen;Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens;Department of Haematology, Liège University Hospital Centre;Department of Medicine, Haematology and Clinical Immunology Branch, University of Padua;Research and Development Department;Department of Biostatistics, Parexel International;Center for Observational Research, Amgen Ltd;Department of Hematology, Fundeni Clinical Institute

关键词: carfilzomib;    multiple myeloma;    proteasome inhibitor;    real world;    relapsed/refractory;   

DOI  :  10.1002/jha2.595

来源: Wiley

【 摘 要 】

Clinical trials have demonstrated the efficacy and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM); however, prospective real-world data are limited. This real-world, prospective, observational study evaluated carfilzomib use, effectiveness and safety in adults with RRMM. Data are presented for a subset of patients (n = 383) who received carfilzomib in combination with lenalidomide and dexamethasone (KRd). The overall response rate (ORR) was 83.6% among 360 evaluable patients. Treatment responses were better when KRd was administered at earlier therapy lines than at later lines of therapy (ORR: second line, 85.3%; third line or later, 81.0%). In patients with the anti-CD38 antibody-refractory disease, ORR was higher when KRd was administered earlier than at later therapy lines (second line/third line, 75.0%; fourth line or later, 60.0%). An ORR of 68.1% and 82.0% was achieved in the lenalidomide-refractory and not lenalidomide-refractory subgroups, respectively. KRd was consistently administered per the European label (twice weekly dose of 27 mg/m2) and the median time to discontinuation was 14.6 months. The safety profile of KRd was consistent with previous studies. These real-world data highlight the effectiveness of KRd as a treatment for patients with RRMM, including those with disease refractory to lenalidomide or anti-CD38 antibodies.

【 授权许可】

Unknown